MRI comes of age in RA clinical trials

Area of Science:

• Rheumatology
• Medical Imaging
• Clinical Trials

Background:

• Modern rheumatoid arthritis (RA) therapies limit placebo use in trials.
• Traditional radiography struggles to differentiate structural progression in RA.
• Active comparator designs are increasingly used in RA randomized controlled trials (RCTs).

Purpose of the Study:

• To evaluate the utility of Magnetic Resonance Imaging (MRI) in assessing structural progression in RA.
• To determine if MRI can serve as a sensitive outcome measure in RA clinical trials.
• To advocate for the regulatory acceptance of MRI in RA trial data.

Main Methods:

• Review of recent RA randomized controlled trials (RCTs) utilizing the RA MRI scoring system (RAMRIS).
• Analysis of MRI's ability to detect synovitis, osteitis, erosions, and cartilage loss.
• Comparison of MRI sensitivity against traditional radiographic measures.

Main Results:

• MRI demonstrated higher sensitivity in assessing joint damage compared to radiographs.
• MRI effectively measured upstream drivers of structural damage like synovitis and osteitis.
• MRI detected significant treatment effects and disease progression at early timepoints (12 weeks).
• MRI findings often predicted subsequent radiographic progression, requiring smaller patient cohorts.

Conclusions:

• MRI, particularly using RAMRIS, is a sensitive tool for evaluating RA progression and treatment efficacy.
• The ability of MRI to detect early changes supports its use in RA clinical trials.
• Regulatory authorities should consider MRI as an alternative to radiography for substantiating claims of structural damage inhibition in RA.